COMMUNIQUÉS West-GlobeNewswire

-
Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference
03/06/2024 -
Publication relating to transparency notifications
03/06/2024 -
Publication relative à des notifications de transparence
03/06/2024 -
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
03/06/2024 -
PROCEPT BioRobotics to Present at Upcoming 2024 Truist Securities MedTech Conference on June 18, 2024
03/06/2024 -
CARVYKTI®▼ (ciltacabtagene autoleucel; cilta-cel) significantly improved progression-free survival and deepened responses versus two standard therapies for patients with functional high-risk multiple myeloma
03/06/2024 -
FibroGen Announces FDA Clearance of Investigational New Drug Application for FG-3165, a Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors
03/06/2024 -
Rhythm Pharmaceuticals Presents Patient-reported Experiences with Hyperphagia in Hypothalamic Obesity at ENDO 2024
03/06/2024 -
Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
03/06/2024 -
HealthEquity Reports First Quarter Ended April 30, 2024 Financial Results
03/06/2024 -
Invivyd to Participate at the Jefferies Global Healthcare Conference
03/06/2024 -
Celcuity To Participate in Jefferies Global Healthcare Conference
03/06/2024 -
BridgeBio to Host Call on Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia on June 4, 2024
03/06/2024 -
Ascendis Pharma Presents New Data and Updated Results from Phase 1/2 IL-Believe Trial at ASCO 2024
03/06/2024 -
CloudMD Announces Filing and Mailing of the Management Information Circular in Connection with the Proposed Go-Private Transaction with CPS Capital
03/06/2024 -
BlueSphere Bio Announces IND Clearance of its First in Human Candidate and New Cell Therapy Portfolio for High-Risk Leukemia Patients
03/06/2024 -
Oxford Treatment Center Launches The Rally Point: Valkyrie Program, a Specialty Program for Female Veterans
03/06/2024 -
Public Hearings on Protecting and Improving Local Hospitals: Community members invited to give input
03/06/2024 -
Late-breaking results from PALOMA-2 study of subcutaneous RYBREVANT®▼ (amivantamab) in combination with lazertinib show clinically meaningful antitumour response and improved safety profile in patients with EGFR-mutated non-small cell lung cancer
03/06/2024
Pages